
CSL Limited
Rating
Updated: Sep 14, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
A detailed description of the company is not yet available.
Latest News
11 days ago · prnewswire.com
Lancet Publication Marks Important Advance in Influenza Prevention for Older AdultsPhase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.
21 days ago · zacks.com
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersTrump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
22 days ago · cnbc.com
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakersNearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.
1 month ago · seekingalpha.com
CSL Limited (CSLLY) Q4 2026 Earnings Call TranscriptCSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
1 month ago · reuters.com
Australia's CSL reports 2% fall in annual profitAustralia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
2 months ago · zacks.com
CSL Q2 Earnings Beat Estimates on Record Sales, Outlook RaisedCarlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments.
2 months ago · reuters.com
CSL to start clinical trials for new immunoglobulin manufacturing processAustralian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same amount of plasma.
2 months ago · prnewswire.com
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE).
3 months ago · prnewswire.com
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European UnionRecommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union (EU) marketing authorisation for TAVNEOS® (avacopan).
11 months ago · seekingalpha.com
CSL Limited (CSLLY) Shareholder/Analyst Call TranscriptCSL Limited (OTCQX:CSLLY) Shareholder/Analyst Call October 27, 2025 7:01 PM EDT Company Participants Fiona Mead - Company Secretary & Head of Corporate Governance Brian McNamee Paul McKenzie - MD, CEO & Executive Director Brian Daniels Cameron Price Megan Clark Conference Call Participants Phoebe Rountree Presentation Fiona Mead Company Secretary & Head of Corporate Governance Good morning, ladies and gentlemen. We still have some people registering, but we always start our Board meetings on time at CSL.
Add to Watchlist
Select watchlists to add or remove CSLLY